Safety and efficacy of a docetaxel-5FU-oxaliplatin regimen with or without trastuzumab in neoadjuvant treatment of localized gastric or gastroesophageal junction cancer: A retrospective study

Christoph Schulz, Frank Kullmann, Volker Kunzmann, Martin Fuchs, Michael Geissler, Ursula Vehling-Kaiser, Heribert Stauder, Axel Wein, Salah-Eddin Al-Batran, Thomas Kubin, Claus Schäfer, Sebastian Stintzing, Clemens Giessen, Dominik Paul Modest, Karsten Ridwelski, Volker Heinemann, NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors. International Journal of Cancer. ,vol. 137, pp. 678- 685 ,(2015) , 10.1002/IJC.29403

Nils Homann, Claudia Pauligk, Kim Luley, Thomas Werner Kraus, Hans-Peter Bruch, Akin Atmaca, Frank Noack, Hans-Michael Altmannsberger, Elke Jäger, Salah-Eddin Al-Batran, Pathological complete remission in patients with oesophagogastric cancer receiving preoperative 5-fluorouracil, oxaliplatin and docetaxel International Journal of Cancer. ,vol. 130, pp. 1706- 1713 ,(2012) , 10.1002/IJC.26180

Karen Becker, Rupert Langer, Daniel Reim, Alexander Novotny, Christian Meyer zum Buschenfelde, Jutta Engel, Helmut Friess, Heinz Hofler, Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: a summary of 480 cases. Annals of Surgery. ,vol. 253, pp. 934- 939 ,(2011) , 10.1097/SLA.0B013E318216F449

Karen Becker, James D. Mueller, Christoph Schulmacher, Katja Ott, Ulrich Fink, Raymonde Busch, Knut Böttcher, J. Rüdiger Siewert, Heinz Höfler, Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer. ,vol. 98, pp. 1521- 1530 ,(2003) , 10.1002/CNCR.11660

Yung-Jue Bang, Eric Van Cutsem, Andrea Feyereislova, Hyun C Chung, Lin Shen, Akira Sawaki, Florian Lordick, Atsushi Ohtsu, Yasushi Omuro, Taroh Satoh, Giuseppe Aprile, Evgeny Kulikov, Julie Hill, Michaela Lehle, Josef Rüschoff, Yoon-Koo Kang, None, Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial The Lancet. ,vol. 376, pp. 687- 697 ,(2010) , 10.1016/S0140-6736(10)61121-X

David Cunningham, William H Allum, Sally P Stenning, Jeremy N Thompson, Cornelis JH Van de Velde, Marianne Nicolson, J Howard Scarffe, Fiona J Lofts, Stephen J Falk, Timothy J Iveson, David B Smith, Ruth E Langley, Monica Verma, Simon Weeden, YKS Viswanath Chua, Yu Jo, MAGIC Trial participants, Nick Wadd, None, Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer The New England Journal of Medicine. ,vol. 355, pp. 11- 20 ,(2006) , 10.1056/NEJMOA055531

Marc Ychou, Valérie Boige, Jean-Pierre Pignon, Thierry Conroy, Olivier Bouché, Gilles Lebreton, Muriel Ducourtieux, Laurent Bedenne, Jean-Michel Fabre, Bernard Saint-Aubert, Jean Genève, Philippe Lasser, Philippe Rougier, Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial Journal of Clinical Oncology. ,vol. 29, pp. 1715- 1721 ,(2011) , 10.1200/JCO.2010.33.0597

Salah-Eddin Al-Batran, Ralf D Hofheinz, Claudia Pauligk, Hans-Georg Kopp, Georg Martin Haag, Kim Barbara Luley, Johannes Meiler, Nils Homann, Sylvie Lorenzen, Harald Schmalenberg, Stephan Probst, Michael Koenigsmann, Matthias Egger, Nicole Prasnikar, Karel Caca, Jörg Trojan, Uwe M Martens, Andreas Block, Wolfgang Fischbach, Rolf Mahlberg, Michael Clemens, Gerald Illerhaus, Katja Zirlik, Dirk M Behringer, Wolff Schmiegel, Michael Pohl, Michael Heike, Ulrich Ronellenfitsch, Martin Schuler, Wolf O Bechstein, Alfred Königsrainer, Timo Gaiser, Peter Schirmacher, Wael Hozaeel, Alexander Reichart, Thorsten O Goetze, Mark Sievert, Elke Jäger, Stefan Mönig, Andrea Tannapfel, Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial The Lancet Oncology. ,vol. 17, pp. 1697- 1708 ,(2016) , 10.1016/S1470-2045(16)30531-9

David Cunningham, Sally P Stenning, Elizabeth C Smyth, Alicia F Okines, William H Allum, Sam Rowley, Laura Stevenson, Heike I Grabsch, Derek Alderson, Thomas Crosby, S Michael Griffin, Wasat Mansoor, Fareeda Y Coxon, Stephen J Falk, Suzanne Darby, Kate A Sumpter, Jane M Blazeby, Ruth E Langley, Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2–3 trial The Lancet Oncology. ,vol. 18, pp. 357- 370 ,(2017) , 10.1016/S1470-2045(17)30043-8

Derek Alderson, David Cunningham, Matthew Nankivell, Jane M Blazeby, S Michael Griffin, Adrian Crellin, Heike I Grabsch, Rupert Langer, Susan Pritchard, Alicia Okines, Richard Krysztopik, Fareeda Coxon, Joyce Thompson, Stephen Falk, Clare Robb, Sally Stenning, Ruth E Langley, Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial Lancet Oncology. ,vol. 18, pp. 1249- 1260 ,(2017) , 10.1016/S1470-2045(17)30447-3